logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Skin Disease, Burns and Wound Care

Results

Drugs

August 2021

Ruxolitinib cream for vitiligo

Ruxolitinib cream is in development for the treatment of vitiligo. Vitiligo is a common chronic skin condition where white patches develop on the skin, commonly on the hands and face. The condition is not life-threatening but can have an impact on self-esteem and wellbeing of sufferers. Risk factors include other autoimmune diseases and family history …

Drugs

June 2021

Baricitinib for treatment of severe alopecia areata in adults

Baricitinib is in clinical development for the treatment of adults with alopecia areata (AA). AA is a disease that develops when the body attacks its own hair follicles (where the hair grows from), which can cause hair loss as small round patches of baldness anywhere on the body. Most commonly, this occurs on the scalp …

Drugs

June 2021

Topical sirolimus for angiofibroma in tuberous sclerosis complex

Topical sirolimus is in clinical development for tuberous sclerosis complex (TSC). TSC is a rare genetic multisystem disorder that is typically apparent shortly after birth. TSC is caused by a mutation (change to genetic material) in one of two different genes (TSC1 or TSC2). Small bumps or red spots, known as angiofibroma, may appear between …

Drugs

May 2021

Spesolimab for the treatment of acute flares of generalised pustular psoriasis

Spesolimab is currently in clinical development for the treatment of acute flares of generalised pustular psoriasis (GPP). Individuals with GPP experience repeated episodes where large surface areas of the skin become inflamed and red, and develop small pus-filled blisters known as pustules. It is a disease that spreads and affects a large surface area of …

Drugs

April 2021

Beremagene geperpavec for dystrophic epidermolysis bullosa

Dystrophic epidermolysis bullosa (DEB) is caused by a mutation in a collagen gene that controls skin strength and stability. This mutation can be inherited from one or both parents, which determines the severity of the condition (those who inherit the mutation from both parents have more severe symptoms). DEB symptoms develop from birth or early …

Drugs

August 2020

BMS-986165 for moderate to severe plaque psoriasis

BMS-986165 is in clinical development for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriasis is an inflammatory disease whereby the body’s immune system becomes over-active resulting in the life cycle of skin cells to drastically speed up. This causes a build-up of red, scaly, flaky and itchy patches of skin to appear that often involve the knees, elbows, scalp and lower back. Plaque psoriasis is thought to be caused by a combination of genetic susceptibility and triggers such as stress, smoking and hormonal changes. Treatment is determined by the area of skin affected and the severity of the plaque psoriasis and may include a combination of topical, phototherapy and systemic (oral or injected) therapies.

Drugs

May 2020

Tralokinumab for adolescents with moderate to severe atopic dermatitis

Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein, interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is administered subcutaneously and is currently licenced for the treatment of adults. Evidence from clinical trials suggests an improvement in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adolescents with moderate to severe AD.

Drugs

February 2020

Abrocitinib for moderate to severe atopic dermatitis

Abrocitinib is a medicinal product taken by mouth (tablets) and acts by selectively blocking a protein called Janus Kinase 1 (JAK-1). JAKs contribute to cell processes that result in an immune or inflammatory response. JAK dependent enzymes are major contributors to the progression of immune-mediated diseases such as AD. Therefore, blocking these enzymes may be beneficial. Abrocitinib, if licensed, may offer the first oral, once-daily treatment option for patients with moderate to severe AD.

Drugs

November 2019

Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years

Secukinumab as a subcutaneous injection is in clinical development for the treatment of enthesitis related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions belong to a group of arthritis conditions of unknown cause known as juvenile idiopathic arthritis which affect children. JPsA patients have arthritis and psoriasis, an inflammatory skin disease and ERA patients have arthritis and enthesitis, inflammation of the ligaments and tendons. These conditions are the result of the immune system mistakenly attacking the body’s own cells at the joints and the skin or tendons, causing swelling, pain and reduced mobility.

Drugs

November 2019

Upadacitinib for atopic dermatitis

Upadacitinib is in development for the treatment of moderate to severe atopic dermatitis (AD). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin …

Get Alerts